116 results about "Kidney problem" patented technology

The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.

A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

A medical monitoring device for monitoring electrical signals from the body of a subject is described. The medical monitoring device monitors electrical signals originating from a cardiac cycle of the subject and associates each cardiac cycle with a time index. The medical monitoring device applies a forward computational procedure to generate a risk score indicative of hyperkalemia, hypokalemia or arrhythmia of the subject. The medical monitoring device can adjust the forward computational procedure based upon clinical data obtained from the subject.

Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

The invention relates to a method and device for dialysis and or bulk fluid removal by generating a fibrosis chamber within a body cavity and performing dialysis or bulk fluid removal. An implantable medical device is described having a fibrosis chamber and a pump. A dialysis chamber and an optional electrodialysis unit can further be provided. An additional controller uses sensory feedback to regulate the fluid levels by altering the extracellular fluid retention within the fibrosis chamber. This device can be used for the treatment of patients with chronic kidney disease who may also be suffering from cardiorenal syndrome and hypertension.

Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.

Devices, systems and methods using feedback from sensors for the treatment of pathological conditions such as Kidney Disease (KD) alone, Heart Failure (HF) alone, KD with concomitant HF or cardiorenal diseases syndrome (CRS) are described. The devices, systems and methods monitor and gather patient information and administer one or more diuretic or natriuretic molecules.

Devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and / or disorders, bone-related diseases and / or disorders, diabetes, cardiovascular disease, renal disease and others.

A novel agent for therapy and / or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and / or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body.

The invention provides a processing method of refined rice suitable for patients suffering from kidney disease. The processing method comprises the following steps: (I) carrying out pretreatment, specifically, soaking the cereal raw material, separating out soaking liquid, crushing and levigating until the particle size is 10-100 meshes; (II) carrying out protease hydrolysis deproteinization; and (III) carrying out dephosphorization: dephosphorizing the cereal raw material subjected to deproteinization in the step (II) by phytase hydrolysis, or addition of yeast for fermentation, or a composite mode of phytase hydrolysis and yeast fermentation, or a composite mode of yeast and lactic acid bacteria microbial fermentation or phytase hydrolysis, yeast and lactic acid bacteria microbial fermentation; separating, cleaning, separating again, drying and crushing; and (IV) performing sieving, mixing, hardening and tempering, preheating, gelatinization, extrusion forming and drying processing on the cereal raw material processed by the step (III) to obtain the refined rice. According to the method provided by the invention, the processes of deproteinization and dephosphorization of the cereal raw material can be finished at a time, the deproteinization rate and the dephosphorization rate are high, and food raw material and products are provided for the patients suffering from kidney disease and other diseases.

The invention discloses a knowledge graph-based cross-department early-diagnosis and decision support system for chronic kidney diseases. The system comprises a patient information model establishmentmodule, a patient information model library storage module, a knowledge graph association module, a knowledge graph reasoning module and a decision support feedback module. According to the invention, a patient information model is constructed, and an OMOP CDM standard term system is utilized to construct electronic medical record data of patients into the patient information model with unified concept codes and unified semantic structures; the advantages of a semantic technology in data interaction and expansion are given to play, so the system has better adaptability and expandability to heterogeneous data of different hospitals; and meanwhile, clinical suggestions obtained through knowledge reasoning based on the knowledge graph are originated from clinical guidelines and doctor experience conforming to evidence-based medicine, and reasoning process and suggestion reasons can be traced and acquired by constructing reasoning instances, so the reasoning process and the suggestion reason can be given while clinical suggestions are given, and the credibility of doctors to decision support suggestions is improved.

The present invention relates to systems, methods and uses for recycling at least a part of water lost during various renal replacement therapy processes, e.g. in the preparation of a fresh dialysate solution or fresh reconstitution fluid for kidney disease dialysis and hemofiltration by utilizing water from the spent fluids. The system of the invention is useful in hemodialysis and in peritoneal dialysis as well as in hemofiltration for reuse of water from filtrates and spent fluids. In addition, the system of the invention is useful in the development of a renal assist device or artificial kidney.

Systems and methods are provided for locally delivering specific prophylactic, regenerative, or therapeutic agents within the body of a patient. Systems and methods can involve direct delivery of prophylactic, regenerative, or therapeutic agents into branch blood vessels or body lumens from a main vessel or lumen, respectively, and in particular into renal arteries extending from an aorta in a patient. Drug infusion techniques encompass specific treatment and prevention regimes for renal diseases including, but not limited to, Acute Kidney Injury, Renal Cell Carcinoma, Polycystic Kidney Disease, and Chronic Kidney Disease.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.

The invention relates to a clinical treatment low-protein food and relative production. Wherein, said method ads alpha modify amidon into wheat amidon, to prepare low-protein food. The invention can realize treatment effect, to support kidney disease patient.

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and / or monitoring of treatment regimens.

The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.

The invention provides a chronic kidney disease screening method and system, and particularly relates to a machine learning method for constructing a chronic kidney disease screening model, which comprises the steps of establishing an effective chronic kidney disease screening model, arranging user data to be screened, substituting the user data to be screened into the chronic kidney disease screening model for model calculation, and finally obtaining a kidney disease risk result. Therefore, the chronic kidney disease screening system is efficient, low in cost and high in accuracy. According to the method, a machine learning BP neural network, XGBoost and a random forest integration algorithm are adopted to train a chronic kidney disease screening model; high-risk groups with chronic kidney diseases can be automatically screened out according to basic body measurement information, symptom information, medical examination information, family history, past history, living habits and other data, and the accuracy reaches up to 0.96 or above.

A biomarker and a technology for utilizing the same, of the present invention, can be useful in the early diagnosis, in urine, of a renal function abnormality due to diabetes and drugs and in the prediction and evaluation of disease severity, and, further, can accurately determine, with high sensitivity and specificity, a renal function abnormality due to diabetes and exposure to drugs, and enablethe early and effective diagnosis of kidney abnormality symptoms through a relatively simple method, thereby being widely usable in various fields, such as in clinical experiments essential for new drug development and in diagnosing drug-causing acute / chronic renal failure, which can frequently occur in the clinical treatment process.

The present invention provides a use of compounds from Antrodia camphorata in manufacturing medicaments for treating kidney diseases, wherein the compounds is represented by formula (I):wherein R1 is a hydrogen atom or acetyl group, R2 iswherein the kidney disease is glomerulosclerosis or glomerulonephritis.

The invention provides a traditional Chinese medicine composition for treating kidney diseases. The traditional Chinese medicine composition mainly comprises herba ephedrae, radix aconiti lateralis preparata, rhizoma zingiberis, roasted rhizoma atractylodis macrocephalae, poria and radix glycyrrhizae preparata. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition has functions of diffusing lungs, strengthening spleens and warming yang to promote diuresis; synergistic effects can be realized by various components in traditional Chinese medicines, accordingly, increase of extra burden on the kidneys of patients can be prevented, excellent clinical treatment effects can be realized by the traditional Chinese medicine composition, and the traditional Chinese medicine composition can become effective fast.

The present invention is directed to a pet food and its use in reducing renal damage in companion animals. More particularly, the pet food maintains muscle mass in animals with renal conditions or animals at risk for developing a renal condition.

The invention relates to an oral traditional Chinese medicine preparation, in particular to a traditional Chinese medicine composition for treating kidney disease and a preparation method thereof. The invention is characterized in that the composition is prepared by the following traditional Chinese medicine raw materials by parts by weight: 20-40 parts of radix pseudostellariae, 15-25 parts of poria cocos, 10-20 parts of salivia chinensis, 10-20 parts of Chinese angelica, 5-15 parts of szechuan lovage rhizome, 5-15 parts of white peony root, 5-15 parts of ophiopogon japonicus, 5-15 parts of Chinese magnoliavine fruit, 5-15 parts of Chinese yam, 5-15 parts of fangji root, 5-15 parts of pawpaw, 20-40 parts of cogongrass rhizome, 10-20 parts of polygonum aviculare, 10-20 parts of fringed pink, 10-20 parts of pyrrosia lingua, 10-20 parts of desmodium, 5-15 parts of pyrrosia lingua, 5-15 parts of health hawthorn and 3-10 parts of prepared liquorice. The medicine can rapidly eliminate oedema and has the effects of reducing frequency of urine, reducing blood pressure and reducing foams in urine, curative effect on kidney disease is obvious, and side effect is less.